Phaseline

Companies › Terran Biosciences Australia

Terran Biosciences Australia: clinical trials, targets and expected readouts

1 active drug program in 4 registered trials: 4 Phase 1; Other; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TR-01-XRR (1) - R-Idazoxan HCL Extended Release (medium release rate)
Alpha-2A adrenergic receptor antagonist
ADRA2APhase 1HealthyDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05727189TR-01-XRR (1) - R-Idazoxan HCL Extended Release (medium release rate)Phase 1HealthyOtherDec 2027
NCT05727189TR-01-XRR (1) - R-Idazoxan HCL Extended Release (medium release rate)Phase 1HealthyOtherDec 2027
NCT05727189TR-01-XRR (1) - R-Idazoxan HCL Extended Release (medium release rate)Phase 1HealthyOtherDec 2027
NCT05727189TR-01-XRR (1) - R-Idazoxan HCL Extended Release (medium release rate)Phase 1HealthyOtherDec 2027

Targets

ADRA2A (1)

Companies with the same targets

Guangzhou Novaken Pharm Santen SAS Pharmazz ARS Pharmaceuticals BioXcel Therapeutics Teikoku Pharma USA Tecnoquimicas Tarian Pharma Alcon Research Acer Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.